HRP20100086T1 - (2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL - Google Patents
(2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL Download PDFInfo
- Publication number
- HRP20100086T1 HRP20100086T1 HR20100086T HRP20100086T HRP20100086T1 HR P20100086 T1 HRP20100086 T1 HR P20100086T1 HR 20100086 T HR20100086 T HR 20100086T HR P20100086 T HRP20100086 T HR P20100086T HR P20100086 T1 HRP20100086 T1 HR P20100086T1
- Authority
- HR
- Croatia
- Prior art keywords
- salt according
- hexahydrophenanthridin
- dimethoxypyridin
- ethoxy
- methoxy
- Prior art date
Links
- NQMAAFUKIUCXHK-MZMPZRCHSA-N (2r,4ar,10br)-6-(2,6-dimethoxypyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol Chemical compound N([C@@H]1CC[C@@H](O)C[C@@H]1C=1C=C(C(=CC=11)OC)OCC)=C1C1=CC=C(OC)N=C1OC NQMAAFUKIUCXHK-MZMPZRCHSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- ANUPWUDEMSBSCA-ZORIOUSZSA-N (2r,4ar,10br)-6-(2,6-dimethoxypyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol;hydrochloride Chemical compound Cl.N([C@@H]1CC[C@@H](O)C[C@@H]1C=1C=C(C(=CC=11)OC)OCC)=C1C1=CC=C(OC)N=C1OC ANUPWUDEMSBSCA-ZORIOUSZSA-N 0.000 claims 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000008023 pharmaceutical filler Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- OPXQOTUWFKHYCC-UHFFFAOYSA-N 1,2,3,4,4a,5-hexahydrophenanthridine Chemical class C1=CC=CC2=CNC(CCCC3)C3=C21 OPXQOTUWFKHYCC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Toxicology (AREA)
Abstract
Spoj, naznačen time, da je (2R,4aR,10bR)-6-(2,6-dimetoksipiridin-3-il)-9-etoksi-8-metoksi-1,2,3,4,4a,10b-heksahidrofenantridin-2-ol hidroklorid. Patent sadrži još 8 patentnih zahtjeva.
Claims (9)
1. Spoj, naznačen time, da je (2R,4aR,10bR)-6-(2,6-dimetoksipiridin-3-il)-9-etoksi-8-metoksi-1,2,3,4,4a,10b-heksahidrofenantridin-2-ol hidroklorid.
2. Spoj, naznačen time, da je solvatni oblik soli u skladu sa zahtjevom 1.
3. Spoj, naznačen time, da je hidratni oblik soli u skladu sa zahtjevom 1.
4. Sol u skladu s bilo kojim zahtjevom 1 do 3, naznačena time, da je u kristaliničnom obliku.
5. Sol u skladu s bilo kojim zahtjevom 1 do 4, naznačena time, da je u krutom dozirnom obliku.
6. Sol u skladu s bilo kojim zahtjevom 1 do 4, naznačena time, da je za uporabu u liječenju bolesti.
7. Farmaceutski pripravak, naznačen time, da sadrži sol u skladu s bilo kojim zahtjevom 1 do 4 zajedno s farmaceutskim pomoćnim tvarima i/ili punilima.
8. Uporaba soli u skladu s bilo kojim zahtjevom 1 do 4, naznačena time, da se koristi za pripremu farmaceutskih pripravaka za liječenje PDE4 posredovanih poremećaja.
9. Uporaba soli u skladu s bilo kojim zahtjevom 1 do 4, naznačena time, da se koristi za pripremu farmaceutskih pripravaka za liječenje diabetes mellitus-a.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05101619 | 2005-03-02 | ||
EP05108442 | 2005-09-14 | ||
PCT/EP2006/060377 WO2006092422A1 (en) | 2005-03-02 | 2006-03-01 | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100086T1 true HRP20100086T1 (hr) | 2010-04-30 |
Family
ID=36295528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100086T HRP20100086T1 (hr) | 2005-03-02 | 2010-02-18 | (2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL |
Country Status (24)
Country | Link |
---|---|
US (4) | US7718668B2 (hr) |
EP (3) | EP1856093B1 (hr) |
JP (2) | JP5478828B2 (hr) |
KR (2) | KR101352687B1 (hr) |
AT (1) | ATE450524T1 (hr) |
AU (1) | AU2006219867B2 (hr) |
BR (1) | BRPI0607645A2 (hr) |
CA (1) | CA2598860C (hr) |
CY (1) | CY1109753T1 (hr) |
DE (1) | DE602006010824D1 (hr) |
DK (1) | DK1856093T3 (hr) |
EA (1) | EA015376B1 (hr) |
ES (2) | ES2337083T3 (hr) |
HR (1) | HRP20100086T1 (hr) |
IL (2) | IL185276A (hr) |
ME (1) | ME01172B (hr) |
MX (1) | MX2007010400A (hr) |
NO (1) | NO339416B1 (hr) |
NZ (2) | NZ589278A (hr) |
PL (1) | PL1856093T3 (hr) |
PT (1) | PT1856093E (hr) |
RS (1) | RS51345B (hr) |
SI (1) | SI1856093T1 (hr) |
WO (1) | WO2006092422A1 (hr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60311662T2 (de) | 2002-08-29 | 2007-10-25 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
CA2556086C (en) | 2004-02-18 | 2014-04-01 | Altana Pharma Ag | Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors |
CN104817534A (zh) | 2004-03-03 | 2015-08-05 | 塔科达有限责任公司 | 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途 |
JP2007527901A (ja) * | 2004-03-10 | 2007-10-04 | アルタナ ファルマ アクチエンゲゼルシャフト | アミド置換された新規のヒドロキシ−6−フェニルフェナントリジン及びpde4インヒビターとしてのそれらの使用 |
PL1856093T3 (pl) | 2005-03-02 | 2010-05-31 | Takeda Gmbh | Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu |
CN101511364B (zh) | 2006-09-07 | 2012-08-15 | 奈科明有限责任公司 | 用于糖尿病的治疗组合 |
WO2009109525A1 (en) * | 2008-03-03 | 2009-09-11 | Nycomed Gmbh | Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease |
JP6038170B2 (ja) | 2011-12-15 | 2016-12-07 | アルカーメス ファーマ アイルランド リミテッド | ブプレノルフィンおよびμ−オピオイド受容体アンタゴニストの組成物 |
CA2936332A1 (en) | 2014-01-22 | 2015-07-30 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier) |
JP7048863B2 (ja) | 2016-08-26 | 2022-04-06 | 武田薬品工業株式会社 | 非アルコール性脂肪肝疾患の治療法 |
JP2020510071A (ja) | 2017-03-16 | 2020-04-02 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特発性肺線維症の治療 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9027055D0 (en) | 1990-12-13 | 1991-02-06 | Sandoz Ltd | Organic compounds |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
EE03523B1 (et) | 1996-01-31 | 2001-10-15 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine |
ES2184077T3 (es) | 1996-03-26 | 2003-04-01 | Altana Pharma Ag | Nuevas fenantridinas sustituidas en la posicion 6. |
US6127378A (en) | 1996-03-26 | 2000-10-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridines substituted in the 6 position |
TR199900856T2 (xx) * | 1996-11-11 | 1999-07-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Bron�la ilgili terapi maddeleri olarak benzonaftiridinler |
WO1998040382A1 (en) | 1997-03-07 | 1998-09-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel tetrazoles |
PT988302E (pt) | 1997-06-03 | 2003-07-31 | Altana Pharma Ag | Benzonaftiridinas |
US6214839B1 (en) * | 1997-07-25 | 2001-04-10 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted 6-alkylphenanthridines |
DE69809754T2 (de) | 1997-07-25 | 2003-09-18 | Altana Pharma Ag | Substituierte 6-phenylphenanthridine |
CZ293725B6 (cs) | 1997-07-25 | 2004-07-14 | Altana Pharma Ag | Tetrazolové deriváty |
DK1075477T3 (da) * | 1998-05-05 | 2003-06-30 | Altana Pharma Ag | Nye benzonaphthyridin-N-oxider |
AU5970199A (en) | 1998-08-31 | 2000-03-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity |
CA2359404A1 (en) * | 1999-01-15 | 2000-07-20 | Beate Gutterer | Phenanthridine-n-oxides with pde-iv inhibiting activity |
ES2241571T3 (es) | 1999-01-15 | 2005-11-01 | Altana Pharma Ag | N-oxidos de fenantrinida con actividad inhividora de pde-iv. |
DE60033918D1 (de) | 1999-01-15 | 2007-04-26 | Altana Pharma Ag | Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung |
PL205670B1 (pl) | 1999-01-15 | 2010-05-31 | Nycomed Gmbh | Nowa 6-fenylofenantrydyna, jej zastosowanie oraz lek zawierający ten związek |
DE60025327T2 (de) * | 1999-01-15 | 2006-08-24 | Altana Pharma Ag | 6-arylphenanthridine mit pde-iv hemmender wirkung |
CA2396026A1 (en) | 2000-01-11 | 2001-07-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridine-n-oxides |
ATE347557T1 (de) | 2000-03-23 | 2006-12-15 | Takeda Pharmaceutical | Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung |
AU2001281965A1 (en) * | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Novel 6-phenylphenanthridines |
AU2001283935B2 (en) | 2000-07-14 | 2006-07-13 | Altana Pharma Ag | Novel 6-heteroarylphenanthridines |
AU2001267589A1 (en) | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines |
DK1377574T3 (da) | 2001-02-21 | 2005-04-25 | Altana Pharma Ag | 6-phenylbenzonaphtyridiner |
WO2004018431A2 (en) | 2002-08-17 | 2004-03-04 | Altana Pharma Ag | Novel phenanthridines |
RS20050117A (en) | 2002-08-17 | 2007-06-04 | Altana Pharma Ag., | Novel benzonaphthyridines |
DE60310576T2 (de) * | 2002-08-29 | 2007-10-31 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer |
DE60311662T2 (de) * | 2002-08-29 | 2007-10-25 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
CA2556086C (en) * | 2004-02-18 | 2014-04-01 | Altana Pharma Ag | Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors |
AR049419A1 (es) * | 2004-03-03 | 2006-08-02 | Altana Pharma Ag | Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo |
CN104817534A (zh) * | 2004-03-03 | 2015-08-05 | 塔科达有限责任公司 | 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途 |
US20070191414A1 (en) * | 2004-03-09 | 2007-08-16 | Altana Pharma Ag | Novel isoamido-substituted hydroxy-6-phenylphenanthridines |
BRPI0508471A8 (pt) | 2004-03-10 | 2019-01-15 | Altana Pharma Ag | compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos |
JP2007527901A (ja) | 2004-03-10 | 2007-10-04 | アルタナ ファルマ アクチエンゲゼルシャフト | アミド置換された新規のヒドロキシ−6−フェニルフェナントリジン及びpde4インヒビターとしてのそれらの使用 |
CA2558390A1 (en) | 2004-03-10 | 2005-09-22 | Altana Pharma Ag | Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
PL1856093T3 (pl) | 2005-03-02 | 2010-05-31 | Takeda Gmbh | Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu |
-
2006
- 2006-03-01 PL PL06708593T patent/PL1856093T3/pl unknown
- 2006-03-01 WO PCT/EP2006/060377 patent/WO2006092422A1/en active Application Filing
- 2006-03-01 NZ NZ589278A patent/NZ589278A/en not_active IP Right Cessation
- 2006-03-01 ES ES06708593T patent/ES2337083T3/es active Active
- 2006-03-01 EP EP06708593A patent/EP1856093B1/en active Active
- 2006-03-01 CA CA2598860A patent/CA2598860C/en not_active Expired - Fee Related
- 2006-03-01 SI SI200630567T patent/SI1856093T1/sl unknown
- 2006-03-01 JP JP2007557507A patent/JP5478828B2/ja not_active Expired - Fee Related
- 2006-03-01 US US11/884,934 patent/US7718668B2/en not_active Expired - Fee Related
- 2006-03-01 AU AU2006219867A patent/AU2006219867B2/en not_active Ceased
- 2006-03-01 PT PT06708593T patent/PT1856093E/pt unknown
- 2006-03-01 BR BRPI0607645-9A patent/BRPI0607645A2/pt not_active Application Discontinuation
- 2006-03-01 AT AT06708593T patent/ATE450524T1/de active
- 2006-03-01 KR KR1020077021911A patent/KR101352687B1/ko not_active IP Right Cessation
- 2006-03-01 ME MEP-2010-34A patent/ME01172B/me unknown
- 2006-03-01 NZ NZ560268A patent/NZ560268A/en not_active IP Right Cessation
- 2006-03-01 DE DE602006010824T patent/DE602006010824D1/de active Active
- 2006-03-01 EA EA200701817A patent/EA015376B1/ru not_active IP Right Cessation
- 2006-03-01 MX MX2007010400A patent/MX2007010400A/es active IP Right Grant
- 2006-03-01 RS RSP-2010/0073A patent/RS51345B/en unknown
- 2006-03-01 EP EP09176620.4A patent/EP2189454B1/en active Active
- 2006-03-01 DK DK06708593.6T patent/DK1856093T3/da active
- 2006-03-01 KR KR1020137022101A patent/KR101421914B1/ko active IP Right Grant
- 2006-03-01 ES ES10177835.5T patent/ES2440590T3/es active Active
- 2006-03-01 EP EP10177835.5A patent/EP2295423B1/en active Active
-
2007
- 2007-08-14 IL IL185276A patent/IL185276A/en not_active IP Right Cessation
- 2007-09-24 NO NO20074843A patent/NO339416B1/no not_active IP Right Cessation
-
2010
- 2010-01-27 CY CY20101100081T patent/CY1109753T1/el unknown
- 2010-02-18 HR HR20100086T patent/HRP20100086T1/hr unknown
- 2010-03-26 US US12/659,977 patent/US8354535B2/en not_active Expired - Fee Related
-
2012
- 2012-12-07 US US13/707,969 patent/US8754218B2/en not_active Expired - Fee Related
-
2013
- 2013-07-21 IL IL227565A patent/IL227565A/en not_active IP Right Cessation
- 2013-10-11 US US14/051,835 patent/US8829189B2/en not_active Expired - Fee Related
- 2013-11-22 JP JP2013241863A patent/JP2014040482A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100086T1 (hr) | (2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL | |
UA99136C2 (ru) | Улучшенная фармацевтическая композиция, содержащая антагонист кальциевых каналов - лерканидипин, способ ее получения | |
IL259851A (en) | Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders | |
ATE465719T1 (de) | Oral zerfallende zusammensetzung von olanzapin oder donepezil | |
DK1487444T3 (da) | Anvendelse af pyridylamider som angiogeneseinhibitorer | |
CL2007002705A1 (es) | Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm. | |
MX2009003184A (es) | Composiciones farmaceuticas que comprenden nilotinib o su sal. | |
JP2008513510A5 (hr) | ||
GB0516168D0 (en) | Pharmaceutical compounds | |
EA200702282A1 (ru) | Комбинация феррохина и производного артемизинина для лечения малярии | |
CR20110209A (es) | Composición farmacéutica sólida | |
BRPI0607214A2 (pt) | derivados de 2-(4-cianofenilamino) pirimidina inibidores de hiv | |
DE602007013040D1 (de) | 4-Ä(3-FLUORPHENOXY)PHENYLMETHYLÜPIPERIDINMETHANiSULFONAT: VERWENDUNGEN, SYNTHESEVERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN | |
NO20074371L (no) | Anthelmintiske imidazol-tiazolderivater | |
ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin | |
ATE412404T1 (de) | Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon | |
ATE489943T1 (de) | Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivate | |
CY1111067T1 (el) | Χρηση της ν-(διβενζ (β,f) οξεπιν-10-υλμεθυλ) -ν-μεθυλ-ν-προπ-2-υνυλαμινης (omigapil) στην προληψη και/ή την θεραπεια της μυϊκης δυστροφiας | |
EA201001095A1 (ru) | Соединение (r)-n*6*-этил-6,7-дигидро-5н-индено[5,6-d]тиазол-2,6-диамин и его применение в качестве антипсихотического средства | |
EA200970167A1 (ru) | Фармацевтическая композиция, содержащая комбинацию саредутанта и селективного ингибитора обратного захвата серотонина или ингибитора обратного захвата серотонина/норэпинефрина | |
ATE415951T1 (de) | Verbesserte pharmazeutische zusammensetzung mit einem ace-hemmer und herstellungsverfahren dafür | |
ITTO20050220A1 (it) | Nuova utilizzazione terapeutica della molsidomina e dei suoi sali farmaceuticamente accettabili | |
WO2019190427A3 (en) | The immediate release combination comprising raloxifene and at least one antipsychotic agent | |
MY150480A (en) | Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof | |
ITCT20050012A1 (it) | Preparato per uso orale, senza additivi, utilizzabile, nella profilassi di vitamina K microdosata, per la prevenzione dell'emorragia neonatale da deficit di ditamina K in forma tardiva. |